CTIS2023-509215-81-00进行中（未招募）1 期
Phase II multicohort trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas - Geis-75
Asoc Grupo Espanol De Investigacion En Sarcomas0 个研究点目标入组 72 人开始时间: 2024年5月8日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Patients must provide written informed consent prior to performance of study-specific procedures and must be willing to comply with treatment and follow up. Informed consent must be obtained prior to start of the screening process. Procedures conducted as part of the patient’s routine clinical management (e.g. blood count, imaging tests, etc.) and obtained prior to signature of informed consent may be used for screening or baseline purposes as long as these procedures are conducted as specified in the protocol., Performance status = 1 (ECOG)., Adequate respiratory functions: FEV1 > 1L; DLCO > 40% (patients with pulmonary target lesions)., Adequate bone marrow function (hemoglobin = 9 g/dL, leukocytes = 3,000/mm3, absolute neutrophil count (ANC) = 1,500/mm3, platelets = 100,000/mm3). Patients with creatinine clearance (based on Cockroft and Gault) =30 ml/min, albumin = 25 g/L, ALT and AST = 2.5 times the ULN, total bilirubin = ULN, CPK = 2.5 times ULN, alkaline phosphatase = 2.5 times the ULN are acceptable. If the increase of alkaline phosphatase is > 2.5 times the ULN, then the alkaline phosphatase liver fraction and/or GGT must be = ULN., Men or women of childbearing potential must use an effective method of contraception before entry into the study and throughout the trial treatment and for 6 months after the last dose of trabectedin. Women of childbearing potential must have a negative urine pregnancy test before study entry., Normal cardiac function with a LVEF = 50% by echocardiogram or MUGA., HBV and HCV serologies must be performed prior to enrollment. If HbsAg is positive it is recommended to reject the existence of replicative phase (HbaAg+, DNA VHB+). If these were positives the inclusion is not recommended, remaining at investigators' discretion the preventive treatment with lamivudine. If a potential patient is positive for anti-HCV antibodies, presence of the virus should be ruled out with a qualitative PCR, or the patient should NOT be included in the study (if a qualitative PCR cannot be performed then patient will not be able to enter the study), Patient must have a central venous catheter for treatment, required for trabectedin administration., Age: 16-75 years., Patients must have a diagnosis of soft tissue sarcoma (cohort A), bone tumors (osteosarcoma, chondrosarcoma) (cohort B) or small round-cell sarcomas (Ewing’s sarcoma, rhabdomyosarcoma, desmoplastic small round-cell tumors and other small round cell sarcomas) (cohort C), with metastasis or locally advanced disease, and not suitable for metastasectomy or surgical resection or not oncologically recommended metastasectomy. A centralized diagnosis will be performed, and the central diagnosis confirmation will be mandatory prior to enrollment (tumor sample must be available and sent during screening)., Disease distribution allows meeting with normal tissue constraints of radiation therapy. Radiation oncologist must confirm this point, taking into account that the dose for extremities will be 45 Gy while for non-extremity will be 30 Gy., Those lesions considered for radiation therapy must be related with a clinically relevant symptom. It is not necessary to irradiate all the lesions within one organ. Irradiating pulmonary lesions with infiltration of pleural serosa should be discouraged., Patients must have documentation of disease progression within 6 months prior to study entry., The patient must have been considered eligible for systemic chemotherapy. Patients sho
排除标准
- •Previous treatment with trabectedin or previous treatment with radiotherapy (this latter just in case the previous radiotherapy treatment does not allow the radiotherapy treatment of this study due to tissue constrains)., Significant systemic diseases grade 3 or higher on the NCI-CTCAE v5.0 scale, that limit patient availability, or according to investigator judgment may contribute significantly to treatment toxicity., Uncontrolled bacterial, mycotic or viral infections., Known positive test for infection by human immunodeficiency virus (HIV)., Women who are pregnant or breast-feeding., Psychological, familiar, social or geographic circumstances that limit the patient’s ability to comply with the protocol or informed consent., Patients who have participated in another clinical trial and/or have received any other investigational product in the last 30 days prior to enrollment., Histologies other than those described in inclusion criteria., Liver inclusion in irradiation fields is not permitted, not even partially., Normal tissue constrains for radiation therapy., Performance status = 2 (ECOG)., Plasma bilirubin > ULN., Creatinine clearance <30ml/min., History of other neoplastic disease with the exception of basal cell carcinoma or in situ cervical cancer adequately treated or no evidence of recurrence for more than 5 years after primary tumor treatment., Severe chronic obstructive pulmonary disease (COPD) or other severe pulmonary diseases., Significant cardiovascular disease (for example, dyspnea > 2 NYHA).
研究者
相似试验
招募中
2 期
Clinical trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas2023-509215-81-00Asoc Grupo Espanol De Investigacion En Sarcomas72
进行中（未招募）
1 期
combination of trabectedin and olaparib in ovarian cancer, fallopian tubes and primary of peritoneum already resistant to standard platinum drugsplatinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneumMedDRA version: 21.1Level: LLTClassification code 10033131Term: Ovarian carcinomaSystem Organ Class: 100000004864EUCTR2018-000230-35-ITFONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS66
进行中（未招募）
1 期
A PHASE II CLINICAL STUDY, ON TRABECTEDIN IN COMBINATION WITH PPARg AGONIST PIOGLITAZONE IN PATIENTS WITH ROUND CELL MYXOID LIPOSARCOMAS OR DEDIFFERENTIATED G1 OR G2 LIPOSARCOMAS WITH STABLE DISEASE IN TREATMENT WITH TRABECTEDIN ALONE.Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluationMedDRA version: 20.0Level: SOCClassification code 10028395Term: Musculoskeletal and connective tissue disordersSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 20.0Level: HLTClassification code 10024628Term: Liposarcomas malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10073139Term: Round cell liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-005626-29-ITIRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI10
进行中（未招募）
1 期
Phase II trial on trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (Cs)EUCTR2015-005153-12-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE43
进行中（未招募）
1 期
Study to Compare a Treatment with Trabectedin and Olaparib to Physician’s Choice in Subjects with Previously Treated Solid Tumors Having a Special lack of Cellular Repair MechanismEUCTR2017-001755-31-DERuprecht-Karls-Universität Heidelberg, Medical Faculty108